New lessons from old drugs

Ovid Technologies (Wolters Kluwer Health) - Tập 50 Số 5 - Trang 1211-1212 - 1998
Christopher G. Goetz1
1From the Rush Presbyterian St. Luke's Medical Center, Chicago, IL.

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1212/WNL.50.1.1

10.1212/WNL.50.1.1

Aoki FY, Sitar DS. Clinical Pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinetic 1988;14:35-51.

Hay AJ. The action of amantadines against influenza A viruses. Semin Virol 1992;3:21-30.

Kulisevsky J Tolosa E. Amantadine and Parkinson's disease. In: Koller WC Paulson G eds. Therapy of Parkinson's disease. New York: M. Dekker 1995:123-136.

Stoof JC, Booij J, Drukalrch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist. Clin Neurol Neurosurg 1992;94:S4-S6.

Blandini F, Porter HP, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996;12:73-94.

Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits. Trends Neurosci 1990;13:266-271.

Shannon KM, Goetz CG, Carroll VS, Tanner CM. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharm 1987;10:522-526.

Greenamyre JT, Eller RV, Zhany Z, Ovaclia A. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661.

10.1159/000180362

Cunningham MA, Darby DG, Donnan GA. Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity and autonomic dysfunction. Neurology 1991;41:942-943.